Working with clinical and academic collaborators, we have successfully completed three clinical studies involving a total of 180 patients, including adults and children, half of whom have PID. The most significant of these being our proof-of-concept study, which included 135 of the patients, with PrimDx achieving an overall accuracy of 95%.
As part of our ongoing research, Immunosis is currently conducting an additional clinical study in patients with severe lung disease, caused by frequent infections. Our interim data from 26 patients has shown an overall diagnostic accuracy of 96%, providing further proof of clinical utility in a real-world scenario. This adds additional support to the use case as up to 10% of patients who present with severe lung disease have PID and their diagnosis is frequently missed.
Our collaboratoring institutions are the Royal Melbourne Hospital, Royal Children’s Hospital and the Walter and Eliza Hall Institute in Melbourne, Victoria
